Literature DB >> 17487353

Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue.

Gina Lama1, Annunziato Mangiola, Carmelo Anile, Giovanni Sabatino, Pasquale De Bonis, Libero Lauriola, Cecilia Giannitelli, Giuseppe La Torre, Meena Jhanwar-Uniyal, Gigliola Sica, Giulio Maira.   

Abstract

Anomalies of growth factor signaling have been reported in malignant human gliomas. The extracellular signal-regulated kinases (ERKs) play a crucial role in transducing growth factor signals to the nucleus and are involved in a wide range of biological responses, including cell proliferation, differentiation and motility. ERK1/2 is expressed and activated in glioblastoma multiforme (GBM). However, no information is available in literature concerning the presence and activity of ERK1/2 in the peritumor tissue. In the present study, we evaluated by immunohistochemistry total and phosphorylated (t and p) ERK1/2 expression in 31 cases of primary GBM and in tissue surrounding the enhanced lesion at different distances up to 3.5 cm from the tumor margin. Total ERK1/2 was, as expected, uniformly expressed not only in GBM but in the areas around the tumor also, which showed higher levels of immunolabeling. ERK1/2 activation was observed in GBM as well as in peritumor tissue, with no statistical difference in the level of the enzymatic activities. In particular, in the peritumor tissue pERK1/2 was present independently of neoplastic cells not only in reactive astrocytes, but in apparently normal glial cells also. These results indicate that ERK1/2 pathway may participate in GBM growth and progression. In addition, they strongly suggest that ERK1/2 stimulation may be linked not only to tissue reactivity to tumor invasion, but also to cell motility or represent per se a sign of transformation. Finally, our findings highlight the meaning of the extension of neoplasm fingers beyond the outer margin of GBM. Patients with neoplastic cells at <10% or without neoplastic cells in peritumor areas showed a higher survival time compared with those with neoplastic elements at > or = 10%. In addition, a percentage > or = 10 of neoplastic elements in peritumor tissue was associated with an approximately 4-fold increased death risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17487353

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  18 in total

1.  Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.

Authors:  L B Nabors; J G Supko; M Rosenfeld; M Chamberlain; S Phuphanich; T Batchelor; S Desideri; X Ye; J Wright; S Gujar; S A Grossman
Journal:  Neuro Oncol       Date:  2011-09-27       Impact factor: 12.300

2.  Leptin activates STAT3 and ERK1/2 pathways and induces endometrial cancer cell proliferation.

Authors:  Yi Liu; Liqun Lv; Wei Xiao; Cheng Gong; Jie Yin; Donghua Wang; Hui Sheng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-06-14

3.  Transferrin receptor 2 is frequently and highly expressed in glioblastomas.

Authors:  Alessia Calzolari; Luigi Maria Larocca; Silvia Deaglio; Veronica Finisguerra; Alessandra Boe; Carla Raggi; Lucia Ricci-Vitani; Francesco Pierconti; Fabio Malavasi; Ruggero De Maria; Ugo Testa; Roberto Pallini
Journal:  Transl Oncol       Date:  2010-04       Impact factor: 4.243

4.  Protein Kinase CK2 Content in GL261 Mouse Glioblastoma.

Authors:  Laura Ferrer-Font; Estefania Alcaraz; Maria Plana; Ana Paula Candiota; Emilio Itarte; Carles Arús
Journal:  Pathol Oncol Res       Date:  2015-10-14       Impact factor: 3.201

5.  Differential gene expression in peritumoral brain zone of glioblastoma: role of SERPINA3 in promoting invasion, stemness and radioresistance of glioma cells and association with poor patient prognosis and recurrence.

Authors:  Vidya P Nimbalkar; Banavathy S Kruthika; Palavalasa Sravya; Shilpa Rao; Harsha S Sugur; Brijesh Kumar Verma; Yasha T Chickabasaviah; Arimappamagan Arivazhagan; Paturu Kondaiah; Vani Santosh
Journal:  J Neurooncol       Date:  2021-01-03       Impact factor: 4.130

Review 6.  Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone.

Authors:  Jean-Michel Lemée; Anne Clavreul; Philippe Menei
Journal:  Neuro Oncol       Date:  2015-07-22       Impact factor: 12.300

7.  Differential Expression of Adenosine P1 Receptor ADORA1 and ADORA2A Associated with Glioma Development and Tumor-Associated Epilepsy.

Authors:  Jun Huang; Ming-Na Chen; Juan Du; Hao Liu; Yu-Jiao He; Guo-Liang Li; Shu-Yu Li; Wei-Ping Liu; Xiao-Yan Long
Journal:  Neurochem Res       Date:  2016-04-02       Impact factor: 3.996

8.  Gene expression profile of glioblastoma peritumoral tissue: an ex vivo study.

Authors:  Annunziato Mangiola; Nathalie Saulnier; Pasquale De Bonis; Daniela Orteschi; Gigliola Sica; Gina Lama; Benedetta Ludovica Pettorini; Giovanni Sabatino; Marcella Zollino; Libero Lauriola; Anna Colabianchi; Gabriella Proietti; Gyula Kovacs; Giulio Maira; Carmelo Anile
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

9.  Assessment of tumor cells in a mouse model of diffuse infiltrative glioma by Raman spectroscopy.

Authors:  Kuniaki Tanahashi; Atsushi Natsume; Fumiharu Ohka; Hiroyuki Momota; Akira Kato; Kazuya Motomura; Naoki Watabe; Shuichi Muraishi; Hitoshi Nakahara; Yahachi Saito; Ichiro Takeuchi; Toshihiko Wakabayashi
Journal:  Biomed Res Int       Date:  2014-08-27       Impact factor: 3.411

10.  Transcriptional signaling pathways inversely regulated in Alzheimer's disease and glioblastoma multiform.

Authors:  Timothy Liu; Ding Ren; Xiaoping Zhu; Zheng Yin; Guangxu Jin; Zhen Zhao; Daniel Robinson; Xuping Li; Kelvin Wong; Kemi Cui; Hong Zhao; Stephen T C Wong
Journal:  Sci Rep       Date:  2013-12-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.